Literature DB >> 1423839

Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes.

H Yamazaki1, Y Inui, C H Yun, F P Guengerich, T Shimada.   

Abstract

An acetyltransferase-overexpressing strain of Salmonella typhimurium (NM2009) has been used to investigate roles of human liver microsomal cytochrome P450 (P450) enzymes in the activation of carcinogenic nitrosamine derivatives, including N-nitrosodialkylamines and tobacco-smoke-related nitrosamines, to genotoxic products. Studies employing correlation of activities with several P450-dependent monooxygenase reactions in different human liver samples, inhibition of microsomal activities by antibodies raised against human P450 enzymes and by specific P450 inhibitors, and reconstitution of activities with purified P450 enzymes suggest that the tobacco-smoke-related nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and N-nitrosonornicotine (NNN) as well as N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) are oxidized to genotoxic products by different P450 enzymes, particularly P450 2E1 and 2A6. The activation of NDMA and NNN by liver microsomes was suggested to be catalyzed more actively by P450 2E1 than by other P450 enzymes because the activities were well correlated with NDMA N-demethylation and aniline p-hydroxylation in different human samples, and purified P450 2E1 had the highest activities in reconstituted monooxygenase systems. The relatively high contribution of P450 2A6 to the activation of NDEA and NNK was supported by the correlation seen with coumarin 7-hydroxylation in human liver microsomes, and antibodies raised against P450 2A6 inhibited both activities by approximately 50%. P450 3A4, 2D6 and 2C enzymes appear not to be extensively involved in the activation of these nitrosamines as judged by several criteria examined. Thus, this work indicates that several P450 enzymes, particularly P450 2E1 and 2A6, catalyze metabolic activation of nitrosamine derivatives including N-nitrosodialkylamines and tobacco-smoke-related nitrosamines in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423839     DOI: 10.1093/carcin/13.10.1789

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  63 in total

1.  Molecular characterization of the Camelus dromedarius putative cytochrome P450s genes.

Authors:  Mohammad Saud Alanazi; Hesham Mahmoud Saeed; Farid Shokry Ataya; Mohammad Dawoud Bazzi
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

Review 2.  Contributions of human enzymes in carcinogen metabolism.

Authors:  Slobodan Rendic; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-05-10       Impact factor: 3.739

3.  CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis.

Authors:  Guo-Wu Zhou; Jia Hu; Qiang Li
Journal:  World J Gastroenterol       Date:  2010-06-21       Impact factor: 5.742

4.  Meta-analyses of the effect of cytochrome P450 2E1 gene polymorphism on the risk of head and neck cancer.

Authors:  Dong Lu; Xiaodan Yu; Yukai Du
Journal:  Mol Biol Rep       Date:  2010-11-13       Impact factor: 2.316

Review 5.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

6.  Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population.

Authors:  R C Sobti; S Sharma; A Joshi; S K Jindal; A Janmeja
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

7.  Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology.

Authors:  Paula M Ferreira; Raquel Catarino; Deolinda Pereira; Ana Matos; Daniela Pinto; Ana Coelho; Carlos Lopes; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2005-12-22       Impact factor: 2.953

8.  A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.

Authors:  Man Ki Ho; Jill C Mwenifumbo; Bin Zhao; Elizabeth M J Gillam; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2008-01       Impact factor: 2.089

Review 9.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

10.  Synergistic metabolic toxicity screening using microsome/DNA electrochemiluminescent arrays and nanoreactors.

Authors:  Sadagopan Krishnan; Eli G Hvastkovs; Besnik Bajrami; Dharamainder Choudhary; John B Schenkman; James F Rusling
Journal:  Anal Chem       Date:  2008-06-19       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.